An adaptive, randomized, placebo-controlled, double-blind, multi-center study of oral FT-4202, a pyruvate kinase activator, in patients with sickle cell disease (SCD).
The Hibiscus Study™ is evaluating the safety and effectiveness of an investigational medication compared with placebo (inactive drug) in people 12 to 65 years of age with SCD. The study is evaluating if the investigational medication can improve anemia and reduce the number of pain crises per year.
Eligible participants must:
- Be 12 to 65 years of age
- Have a confirmed diagnosis of SCD
- Have had at least 2 pain episodes (vaso-occlusive crises) within the past 12 months
- Not have had more than 10 vaso-occlusive crises within the past 12 months
- Be willing and able to follow all study requirements and study visit schedules
There are additional eligibility requirements, which the study doctor will explain to you. To learn more about study participation, and to see if you or someone you know may qualify, visit or Hibiscusstudy.com/SCDAA 844-608-0808 to complete the prescreening questionnaire.